Rescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Cystic fibrosis (CF) is a fatal genetic disease caused by mutations in cftr, a gene encoding a PKA-regulated Cl−channel. The most common mutation results in a deletion of phenylalanine at position 508 (ΔF508-CFTR) that impairs protein folding, trafficking, and channel gating in epithelial cells. In the airway, these defects alter salt and fluid transport, leading to chronic infection, inflammation, and loss of lung function. There are no drugs that specifically target mutant CFTR, and optimal treatment of CF may require repair of both the folding and gating defects. Here, we describe two classes of novel, potent small molecules identified from screening compound libraries that restore the function of ΔF508-CFTR in both recombinant cells and cultures of human bronchial epithelia isolated from CF patients. The first class partially corrects the trafficking defect by facilitating exit from the endoplasmic reticulum and restores ΔF508-CFTR-mediated Cl−transport to more than 10% of that observed in non-CF human bronchial epithelial cultures, a level expected to result in a clinical benefit in CF patients. The second class of compounds potentiates cAMP-mediated gating of ΔF508-CFTR and achieves single-channel activity similar to wild-type CFTR. The CFTR-activating effects of the two mechanisms are additive and support the rationale of a drug discovery strategy based on rescue of the basic genetic defect responsible for CF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA
Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., et al. (1989) · Science · doi:10.1126/science.2475911 · Cited by 7,418
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · cited 1×
“1C, the 1-z screening window parameter (63) was 0.”
BackgroundCheng, S. H., Gregory, R. J., Marshall, J., Paul, S., Souza, D. W., White, G. A., O'Riordan, C. R., & Smith, A. E. (1990) · Cell · doi:10.1016/0092-8674(90)90148-8 · Cited by 1,792
Degradation of CFTR by the ubiquitin-proteasome pathway
Ward, C. L., Omura, S., & Kopito, R. R. (1995) · Cell · doi:10.1016/0092-8674(95)90240-6 · Cited by 1,304
Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive
Denning, G. M., Anderson, M. P., Amara, J. F., Marshall, J., Smith, A. E., & Welsh, M. J. (1992) · Nature · doi:10.1038/358761a0 · Cited by 1,234
Matsui, H., Grubb, B. R., Tarran, R., Randell, S. H., Gatzy, J. T., Davis, C. W., & Boucher, R. C. (1998) · Cell · doi:10.1016/s0092-8674(00)81724-9 · Cited by 1,169
Structure and Function of the CFTR Chloride Channel
SHEPPARD, D. N., & WELSH, M. J. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.1.s23 · Cited by 1,018
Mutations in the Cystic Fibrosis Gene in Patients with Congenital Absence of the Vas Deferens
Chillón, M., Casals, T., Mercier, B., Bassas, L., Lissens, W., Silber, S., Romey, M.-C., Ruiz-Romero, J., Verlingue, C., Claustres, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506013322204 · Cited by 952
Low access resistance perforated patch recordings using amphotericin B
Rae, J., Cooper, K., Gates, P., & Watsky, M. (1991) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(91)90017-t · Cited by 917
Davis, P. B., Drumm, M., & Konstan, M. W. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.154.5.8912731 · Cited by 764
Cited by
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. P. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,648
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J. C., De Boeck, K., Flume, P. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409547 · Cited by 1,622
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A., Joubran, J., Hazlewood, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904709106 · Cited by 1,228
Self-citationCorrection of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., McCartney, J., Olson, E. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105787108 · Cited by 1,088
“Such agents are called CFTR correctors (18, 19).”
BackgroundMethodSelf-citationThe future of cystic fibrosis care: a global perspective
Bell, S. C., Mall, M. A., Gutierrez, H., Macek, M., Madge, S., Davies, J. C., Burgel, P.-R., Tullis, E., Castaños, C., Castellani, C., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30337-6 · Cited by 974
Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
Taylor-Cousar, J. L., Munck, A., McKone, E. F., van der Ent, C. K., Moeller, A., Simard, C., Wang, L. T., Ingenito, E. P., McKee, C., Lu, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709846 · Cited by 794
CFTR Function and Prospects for Therapy
Riordan, J. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142532 · Cited by 610
CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine
Lopes-Pacheco, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01662 · Cited by 535
Chloride channels as drug targets
Verkman, A. S., & Galietta, L. J. V. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2780 · Cited by 469
Younger, J. M., Chen, L., Ren, H.-Y., Rosser, M. F. N., Turnbull, E. L., Fan, C.-Y., Patterson, C., & Cyr, D. M. (2006) · Cell · doi:10.1016/j.cell.2006.06.041 · Cited by 440
Guerriero, C. J., & Brodsky, J. L. (2012) · Physiological Reviews · doi:10.1152/physrev.00027.2011 · Cited by 418
Jung, T., Catalgol, B., & Grune, T. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.04.001 · Cited by 389
Villella, V. R., Esposito, S., Bruscia, E. M., Maiuri, M. C., Raia, V., Kroemer, G., & Maiuri, L. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00001 · Cited by 389
CFTR: folding, misfolding and correcting the ΔF508 conformational defect
Lukacs, G. L., & Verkman, A. S. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.10.003 · Cited by 375
Phenotypic drug discovery: recent successes, lessons learned and new directions
Vincent, F., Nueda, A., Lee, J., Schenone, M., Prunotto, M., & Mercola, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00472-w · Cited by 348
Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation
Flume, P. A., Liou, T. G., Borowitz, D. S., Li, H., Yen, K., Ordoñez, C. L., & Geller, D. E. (2012) · Chest · doi:10.1378/chest.11-2672 · Cited by 338
Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis
Cholon, D. M., Quinney, N. L., Fulcher, M. L., Esther, C. R., Das, J., Dokholyan, N. V., Randell, S. H., Boucher, R. C., & Gentzsch, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008680 · Cited by 320
Eckford, P. D. W., Li, C., Ramjeesingh, M., & Bear, C. E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.393637 · Cited by 309
Ratjen, F., Hug, C., Marigowda, G., Tian, S., Huang, X., Stanojevic, S., Milla, C. E., Robinson, P. D., Waltz, D., Davies, J. C., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30215-1 · Cited by 294
Ren, H. Y., Grove, D. E., De La Rosa, O., Houck, S. A., Sopha, P., Van Goor, F., Hoffman, B. J., & Cyr, D. M. (2013) · Molecular Biology of the Cell · doi:10.1091/mbc.e13-05-0240 · Cited by 284
Self-citationRabeh, W. M., Bossard, F., Xu, H., Okiyoneda, T., Bagdany, M., Mulvihill, C. M., Du, K., di Bernardo, S., Liu, Y., Konermann, L., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.024 · Cited by 280
Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis
Robinson, E., MacDonald, K. D., Slaughter, K., McKinney, M., Patel, S., Sun, C., & Sahay, G. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.014 · Cited by 272
Requirements for efficient correction of ΔF508 CFTR revealed by analyses of evolved sequences
Mendoza, J. L., Schmidt, A., Li, Q., Nuvaga, E., Barrett, T., Bridges, R. J., Feranchak, A. P., Brautigam, C. A., & Thomas, P. J. (2012) · Cell · doi:10.1016/j.cell.2011.11.023 · Cited by 261
CFTR: cystic fibrosis and beyond
Mall, M. A., & Hartl, D. (2014) · European Respiratory Journal · doi:10.1183/09031936.00228013 · Cited by 259
A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect
Boyle, M. P., & De Boeck, K. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(12)70057-7 · Cited by 244
Mall, M. A., Mayer-Hamblett, N., & Rowe, S. M. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201910-1943so · Cited by 229
Do you know the sex of your cells?
Shah, K., McCormack, C. E., & Bradbury, N. A. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00281.2013 · Cited by 219
“A similar dearth of sex data is seen in other reports on the identification and development of other drugs for the treatment of patients with cystic fibrosis (268, 269).”
The Δ F508 Mutation Causes CFTR Misprocessing and Cystic Fibrosis–Like Disease in Pigs
Ostedgaard, L. S., Meyerholz, D. K., Chen, J.-H., Pezzulo, A. A., Karp, P. H., Rokhlina, T., Ernst, S. E., Hanfland, R. A., Reznikov, L. R., Ludwig, P. S., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001868 · Cited by 200
“These discoveries sparked an effort by academia and industry to therapeutically correct the CFTR-DF508 defects (10, 11).”
BackgroundCystic Fibrosis Transmembrane Regulator Correctors and Potentiators
Rowe, S. M., & Verkman, A. S. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009761 · Cited by 176
“Screening by Vertex Pharmaceuticals has yielded other classes of correctors (Van Goor et al. 2006, 2010), with the most promising compound, VX-809, in phase II clinical trials as discussed below.”
BackgroundMethodCFTR modulator therapy: Transforming the landscape of clinical care in cystic fibrosis
Taylor-Cousar, J. L., Robinson, P. D., Shteinberg, M., & Downey, D. G. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01609-4 · Cited by 173
Ion Channel Modulators in Cystic Fibrosis
Gentzsch, M., & Mall, M. A. (2018) · Chest · doi:10.1016/j.chest.2018.04.036 · Cited by 172
Milla, C. E., Ratjen, F., Marigowda, G., Liu, F., Waltz, D., & Rosenfeld, M. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201608-1754oc · Cited by 168
Chen, H.-K., Liu, Z., Meyer-Franke, A., Brodbeck, J., Miranda, R. D., McGuire, J. G., Pleiss, M. A., Ji, Z.-S., Balestra, M. E., Walker, D. W., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.276162 · Cited by 163
Pranke, I. M., Hatton, A., Simonin, J., Jais, J. P., Le Pimpec-Barthes, F., Carsin, A., Bonnette, P., Fayon, M., Stremler-Le Bel, N., Grenet, D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-07504-1 · Cited by 161
Mahley, R. W., & Huang, Y. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3008618 · Cited by 132
Convertino, M., Das, J., & Dokholyan, N. V. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00195 · Cited by 105
Awatade, N. T., Wong, S. L., Hewson, C. K., Fawcett, L. K., Kicic, A., Jaffe, A., & Waters, S. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01429 · Cited by 92
Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR
Rowe, S. M., McColley, S. A., Rietschel, E., Li, X., Bell, S. C., Konstan, M. W., Marigowda, G., Waltz, D., & Boyle, M. P. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201609-689oc · Cited by 92
Ren, C. L., Morgan, R. L., Oermann, C., Resnick, H. E., Brady, C., Campbell, A., DeNagel, R., Guill, M., Hoag, J., Lipton, A., et al. (2018) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201707-539ot · Cited by 74
Air-Liquid interface cultures to model drug delivery through the mucociliary epithelial barrier
Lee, R. E., Reidel, B., Nelson, M. R., Macdonald, J. K., Kesimer, M., & Randell, S. H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114866 · Cited by 71
Metadata
- Authors
- Van Goor, F., Straley, K. S., Cao, D., González, J., Hadida, S., Hazlewood, A., Joubran, J., Knapp, T., Makings, L. R., Miller, M., Neuberger, T., Olson, E., Panchenko, V., Rader, J., Singh, A., Stack, J. H., Tung, R., Grootenhuis, P. D. J., & Negulescu, P.
- Venue
- American Journal of Physiology-Lung Cellular and Molecular Physiology
- Publisher
- American Physiological Society
- Published
- 2006-06
- Volume
- 290
- Issue
- 6
- Pages
- L1117-L1130
- ISSN
- 1040-0605 (ISSN-L)
- 1522-1504
- OpenAlex
- W2125460059
- Cited by
- 512
- References
- 56
- FWCI
- 21.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.